Phase 2 Lung Cancer Trial, Recruiting NCT06910761 Sponsor: City of Hope Medical Center Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT06910761
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given written consent to participate (or whose legal representative has done so on their behalf)
  • People aged 18 or older
  • People who have a reasonable level of physical functioning, as measured by a standard health scale called the Karnofsky Performance Status (score of 60 or above) (confirm with trial site)
  • People who can read and understand English or Spanish, or who are able to complete questionnaires with the help of a certified interpreter
  • People who have been diagnosed with breast cancer or non-small cell lung cancer, confirmed through a tissue sample
  • People whose cancer has spread to the lining around the brain and spinal cord (called leptomeningeal disease), confirmed by scan or spinal fluid test
  • People whose blood counts and kidney function meet certain minimum levels, including white blood cells, red blood cells, platelets, and kidney filtering ability (confirm with trial site for specific values)
  • Women who could become pregnant must have a negative pregnancy test before starting the trial
  • People of childbearing potential who agree to use effective birth control or avoid heterosexual activity during the trial and for at least one month after the last treatment

Who may not be able to join:

  • People who have received chemotherapy, biological therapy, or immunotherapy within 7 days before the trial start date
  • People whose prior radiation treatment, in the opinion of the treating doctor, would make it unsafe to receive radiation to the brain and spine as part of this trial
  • People who have multiple or serious neurological symptoms, such as confusion or brain swelling, as determined by the treating doctor
  • People who have widespread cancer outside the brain and spine that is not under control
  • People for whom, in the treating doctor's opinion, there are no reasonable remaining treatment options for their cancer overall
  • People with other serious uncontrolled medical conditions, as determined by the treating doctor
  • People with a history of HIV infection, unless they are on effective treatment and their viral load has been undetectable within the past 6 months
  • People with a history of chronic hepatitis B infection, unless their viral load is undetectable and they are on suppressive therapy
  • People with a history of hepatitis C infection, unless they have been successfully treated and cured, or are currently on treatment with an undetectable viral load
  • People with another active cancer, unless the treating doctor considers it unlikely to interfere with the safety or results of this trial
  • People who are pregnant or breastfeeding
  • People who are unable to have an MRI scan of the brain and spine with contrast dye (gadolinium)
  • People who, in the treating doctor's opinion, may not be able to follow all study procedures for any reason
  • People with any other condition that the treating doctor considers would make participation unsafe

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
5 May 2025
Est. completion
2 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Central nervous system (CNS)-progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov